{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:40:15Z","timestamp":1792309215887,"version":"4.4.0"},"reference-count":21,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Accurate preoperative differentiation between non\u2013muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is critical for selecting appropriate therapy. We prospectively evaluated the diagnostic performance of multiparametric MRI (mpMRI) using the Vesical Imaging\u2013Reporting and Data System (VI-RADS) for predicting pathological muscle invasion in patients with suspected bladder tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this prospective cohort study, 102 consecutive adults with suspected bladder mass were enrolled; 53 patients formed the final analytic cohort (24 MIBC, 29 NMIBC). mpMRI was performed on a 3T scanner; the highest VI-RADS score was used for patients with multiple lesions. Two blinded radiologists assigned VI-RADS scores. The reference standard was histopathology obtained after Transurethral resection of bladder tumor. Diagnostic performance metrics were calculated with 95% confidence intervals, and area under curve (AUC) analysis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All mpMRI scans were interpretable, with no serious adverse events. Muscle invasion was observed in 37.5% of VI-RADS 4 lesions and 94.7% of VI-RADS 5 lesions. At VI-RADS\u2009\u2a7e\u20093, sensitivity was 100% and specificity 37.9% (accuracy 66.0%; AUC 0.69). At VI-RADS\u2009\u2a7e\u20094, sensitivity remained 100% with improved specificity 62.1% (accuracy 79.2%; AUC 0.81). Using VI-RADS 5 as positive yielded specificity 96.6% with sensitivity 75% (accuracy 86.8%; AUC 0.86).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>VI-RADS on mpMRI demonstrated excellent sensitivity for ruling out MIBC at lower thresholds, while higher thresholds improved specificity for ruling in muscle invasion. These findings support VI-RADS-guided preoperative risk stratification, with larger multicenter validation warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603261450690","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T08:49:47Z","timestamp":1779871787000},"page":"682-687","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective cohort study to assess the diagnostic accuracy of VI-RADS score in a tertiary center in central India"],"prefix":"10.1177","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4048-6884","authenticated-orcid":false,"given":"Sagar","family":"Yadav","sequence":"first","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Madhavan","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Sharda University, Greater Noida, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2588-9041","authenticated-orcid":false,"given":"Udit","family":"Khurana","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5408-3656","authenticated-orcid":false,"given":"Shubham Singh","family":"Bais","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences (AIIMS), Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Witjes JA Bruins HM Carri\u00f3n A et al. European Association of Urology Guidelines on Muscle-invasive and metastatic bladder cancer: Summary of the 2023 Guidelines. Eur Urol 2024; 85(1): 17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016","DOI":"10.1016\/j.eururo.2024.03.002"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"National Cancer Registry Programme Investigator Group. Cancer incidence mortality years of life lost years lived with disability and disability-adjusted life-years for 29 cancer groups in India 2010 to 2019: the Global Burden of Disease Study 2019. JAMA Netw Open 2025; 8(8): e2527805. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.27805","DOI":"10.1001\/jamanetworkopen.2025.27805"},{"issue":"2","key":"e_1_3_3_4_2","first-page":"43","article-title":"Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies","volume":"22","author":"Matulewicz RS","year":"2020","unstructured":"Matulewicz RS, Steinberg GD. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol 2020; 22(2): 43\u201351.","journal-title":"Rev Urol"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Grabe-Heyne K Henne C Mariappan P et al. Practical considerations for the surgical and intravesical management of non-muscle invasive bladder cancer. Front Oncol 2023; 13: 1200800. https:\/\/doi.org\/10.3389\/fonc.2023.1200800","DOI":"10.3389\/fonc.2023.1170124"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Kim LHC Patel MI. Transurethral resection of bladder tumour (TURBT). Transl Androl Urol 2020; 9(6): 3056\u20133072. https:\/\/doi.org\/10.21037\/tau.2019.09.38","DOI":"10.21037\/tau.2019.09.38"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Panebianco V Narumi Y Altun E et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-reporting and Data System). Eur Urol 2018; 74(3): 294\u2013306. https:\/\/doi.org\/10.1016\/j.eururo.2018.04.029","DOI":"10.1016\/j.eururo.2018.04.029"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Cumberbatch MGK Foerster B Catto JWF et al. Repeat transurethral resection in Non-muscle-invasive bladder cancer: a systematic review. Eur Urol 2018; 73(6): 925\u2013933. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.014","DOI":"10.1016\/j.eururo.2018.02.014"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Balbay MD Cimentepe E Unsal A et al. The actual incidence of bladder perforation following transurethral bladder surgery. J Urol 2005; 174(6): 2260\u2013NaN2 discussion 2262. https:\/\/doi.org\/10.1097\/01.ju.0000181828.30850.0d","DOI":"10.1097\/01.ju.0000181811.61199.35"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Del Giudice F Flammia RS Pecoraro M et al. The accuracy of Vesical Imaging-reporting and Data System (VI-RADS): an updated comprehensive multi-institutional multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J Urol 2022; 40(7): 1617\u20131628. https:\/\/doi.org\/10.1007\/s00345-022-03969-6","DOI":"10.1007\/s00345-022-03969-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"Wang H Luo C Zhang F et al. Multiparametric MRI for bladder cancer: Validation of VI-RADS for the detection of detrusor muscle invasion. Radiology 2019; 291(3): 668\u2013674. https:\/\/doi.org\/10.1148\/radiol.2019182506","DOI":"10.1148\/radiol.2019182506"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Humphrey PA Moch H Cubilla AL et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours. Eur Urol 2016; 70(1): 106\u2013119. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.028","DOI":"10.1016\/j.eururo.2016.02.028"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Islam NU Jehangir M Parry AH et al. Diagnostic performance of multiparametric MRI based Vesical Imaging-Reporting and Data System (VI-RADS) scoring in discriminating between non-muscle invasive and muscle invasive bladder cancer. Pol J Radiol 2023; 88: e356\u2013e364. https:\/\/doi.org\/10.5114\/pjr.2023.130807","DOI":"10.5114\/pjr.2023.130807"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Woo S Panebianco V Narumi Y et al. Diagnostic performance of Vesical Imaging Reporting and data system for the prediction of muscle-invasive bladder cancer: A systematic review and meta-analysis. Eur Urol Oncol 2020; 3(3): 306\u2013315. https:\/\/doi.org\/10.1016\/j.euo.2020.02.007","DOI":"10.1016\/j.euo.2020.05.005"},{"key":"e_1_3_3_15_2","unstructured":"Reddy V Alva G Sutrave A et al. Diagnostic Accuracy of Vesical Imaging Reporting and Data System (VI-RADS) in Detection of Muscle Invasive Bladder Cancer. Indian J Urol 2024; 40: 224\u2013229. https:\/\/doi.org\/10.4103\/iju.iju_260_24"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Liu S Xu F Xu T et al. Evaluation of Vesical Imaging-reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. Transl Androl Urol 2020; 9(2): 445\u2013451. https:\/\/doi.org\/10.21037\/tau.2020.02.16","DOI":"10.21037\/tau.2020.02.16"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"S\u00e9guier-Puech D Soubeyran I Renard-Penna R et al. Evaluation of Vesical imaging-reporting and data system (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. Ther Adv Urol 2021; 13: 17562872211039583. https:\/\/doi.org\/10.1177\/17562872211039583","DOI":"10.1177\/17562872211039583"},{"key":"e_1_3_3_18_2","unstructured":"Al-Qudimat AR Sabir J. Diagnostic performance of multiparametric MRI with vesical imaging reporting and data system (VI-RADS) in assessing muscle invasion in bladder cancer. Arab J Urol 2024; 22: 81\u201389. https:\/\/doi.org\/10.1080\/2090598X.2024.2314766"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Bicchetti M Simone G Giannarini G et al. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. Radiol Med 2022; 127(8): 881\u2013890. https:\/\/doi.org\/10.1007\/s11547-022-01513-5","DOI":"10.1007\/s11547-022-01513-5"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","unstructured":"Wang Z Shang Y Luan T et al. Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer. Cancer Imaging 2020; 20: 73. https:\/\/doi.org\/10.1186\/s40644-020-00304-3","DOI":"10.1186\/s40644-020-00304-3"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"Del Giudice F Pecoraro M Vargas HA et al. Systematic Review and meta-analysis of Vesical Imaging-reporting and Data System (VI-RADS) inter-observer Reliability: an added value for muscle invasive bladder cancer detection. Cancers 2020; 12(10): 2994. https:\/\/doi.org\/10.3390\/cancers12102994","DOI":"10.3390\/cancers12102994"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Bizzarri FP Nelson AW Colquhoun AJ et al. Utility of fluorodeoxyglucose positron emission tomography\/computed tomography in detecting lymph node involvement in comparison to conventional imaging in patients with bladder cancer with variant histology. Eur Urol Oncol 2025; 8(6): 1459\u20131460. https:\/\/doi.org\/10.1016\/j.euo.2025.03.019","DOI":"10.1016\/j.euo.2025.03.019"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261450690","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261450690","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261450690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:07:07Z","timestamp":1792307227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261450690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/03915603261450690"],"URL":"https:\/\/doi.org\/10.1177\/03915603261450690","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}